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Clostridioides difficile is the primary cause of antibiotic-associ-
ated diarrhea and colitis, a healthcare-associated intestinal disease
resulting in a significant fatality rate. Colonization of the gut is
critical forC. difficilepathogenesis. Thebacterialmolecules essen-
tial for efficient colonization therefore offer great potential as vac-
cine candidates. Here we present findings demonstrating that the
C. difficile immunogenic lipoproteinCD0873playsacritical role in
pathogen success in vivo. We found that in a dixenic colonization
model, a CD0873-positive strain of C. difficile significantly out-
competed a CD0873-negative strain. Immunization of mice with
recombinant CD0873 prevented long-term gut colonization and
was correlated with a strong secretory IgA immune response. We
further present high-resolution crystal structures of CD0873, at
1.35–2.50 A˚ resolutions, offering a first view of the ligand-binding
pocket ofCD0873andprovide evidence that this lipoprotein adhe-
sin is part of a tyrosine import system, an amino acid key inC. dif-
ficile infection. These findings suggest that CD0873 could serve as
an effective component in a vaccine againstC. difficile.
In recent years, standardmethods of treatment have become
increasingly ineffective against antibiotic-associated diarrhea
caused by Clostridioides difficile. Together with the emergence
of epidemic and hypervirulent lineages, this has resulted in
C. difficile infection (CDI)6 becoming an ever-growing burden
on healthcare systems (1, 2). The economics of C. difficile vac-
cines have been modeled, demonstrating that a vaccine against
C. difficile is economically viable and urgently required (3, 4). It
has beenproposed that aC. difficile vaccine should provide cov-
erage against several pathogenic strains, prevent gastrointesti-
nal colonization, or block cellular toxicity by secreted toxins (5).
The most advanced vaccines trialed to date have focused pre-
dominantly on the C. difficile toxins alone, with some still the
focus of clinical trials, whereas others having been withdrawn
(5, 6). Many have suggested the development of vaccines that
target the initial stages of CDI, such as colonization of the gut
via adhesion to host cells, as a complementary strategy for new
vaccines (7).
Several C. difficile surface molecules have been investigated
as putative adhesion and colonization factors (8). These
include, but are not limited to, members of the family of cell
wall proteins (Cwp), the S-layer proteins (SLP), microbial sur-
face components recognizing adhesive matrix molecules
(MSCRAMMs) including fibronectin-binding protein (Fbp68/
FbpA) and collagen-binding protein (CbpA) (9). Other proteins
reported to have a role inC. difficile adherence are components
of the flagellar apparatus, although these have been shown to
function in a strain-dependent manner (10). The C. difficile
antigen CD0873 is annotated as a substrate-binding protein
component (SBP) of an ATP-binding cassette (ABC) trans-
porter (11) and is an immunoreactive protein in human infec-
tion (12). We have previously shown, using both genetic and
cellular approaches, that CD0873 is a surface-exposed lipopro-
tein and an adhesin of C. difficile (13).
Here we used a competitive murine model to demonstrate
that a CD0873-deficient strain of C. difficile shows a long-term
decrease in colonization fitness.We show that purifiedCD0873
can protect against long-term persistence in a conventional
murine active immunization model, with a corresponding spe-
cific adaptive immune response to CD0873. We present three
high-resolution structures of CD0873, which possesses a typi-
cal Class I SBP fold: a near-atomic resolution closed, ligand-
bound structure, an open, ligand-bound structure, and an open,
ligand-free structure. The structural and biochemical informa-
tion reported in this study demonstrates that tyrosine is the
ligand of CD0873. Given the importance of tyrosine metabo-
lism in C. difficile persistence, through 4-methylphenol (para-
cresol) production, these data provides essential information
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on this phenomenon (14, 15). To the best of our knowledge, we
present the first crystal structures of a known Class I SBP adhe-
sin. This report provides detailed characterization of a C. diffi-
cile protein, CD0873, which should be considered as a compo-
nent of future vaccines to prevent C. difficile colonization.
Results
WTC. difficile outcompetes a CD0873mutant in a dixenic
murinemodel of colonization
It has previously been shown that the lipoprotein CD0873
facilitates adherence of C. difficile to human enterocytes (13).
We therefore hypothesized that CD0873 may confer a fitness
advantage to C. difficile in a dixenic murine model of coloniza-
tion. To test this hypothesis, germ-free mice were co-chal-
lenged with wildtype (WT, 630erm) and CD0873-inactivated
C. difficile, KO strain (KSA1). Initially, both strains exhibited
similar levels of colonization as observed by the bacteria shed in
the feces at D(day)1 post-challenge (Fig. 1A). Bacterial fitness of
the WT strain was significantly higher than the mutant KSA1
strain at D10 (p 0.0043) and D15 (p 0.025) after challenge,
showing a higher level of bacterial shedding in feces (Fig. 1A).
Study of the caecal content showed a decrease of the KSA1
strain at D15 compared with the WT 630erm (Fig. 1B). The
level of mucosa-associated bacteria was analyzed to assess the
role of the lipoprotein CD0873 in vivo adhesion ofC. difficile to
gutmucosa. Although nonsignificant, at D15, a partial decrease
of mucosa-associated KSA1 was observed compared with the
WT strain (Fig. 1C). Taken together, these results indicate that,
in this in vivo model, WT C. difficile outcompetes a CD0873
insertional mutant strain, suggesting that the lipoprotein
CD0873 has a role in C. difficile gut colonization.
Inactivation of the lipoprotein CD0873 reduces in vivo
colonization by C. difficile in a conventional murinemodel of
infection
To further investigate the role of the lipoprotein CD0873 in
CDI in vivo, the gut colonization ability of the CD0873 mutant
strain of C. difficile, KSA1, was analyzed relative to that of its
parental WT strain 630erm in conventional mice that have a
complex (although dysbiotic) gut microbiota. This previously
developed reference mouse model of colonization mimics
C. difficile infection associated with antibiotic treatment (16).
Two groups of 15micewere orally challengedwith eitherC. dif-
ficile 630erm or KSA1. Most of the infected mice developed
diarrhea by D2 after challenge. However, fecal shedding of bac-
teria was significantly lower at D6 (p 0.001), D8 (p 0.012),
and D13 (p  0.0075), from mice challenged with KSA1 com-
pared with mice challenged with 630erm. This shows there is
a significant and lasting decrease in colonization by theCD0873
mutant comparedwith theWT strain (Fig. 2A). Colonization of
the gut by KSA1 was below the limit of detection at D13,
whereas the WT remained detectable. These results were mir-
roredwith the observation of a significantly lower level of KSA1
in the caecal content comparedwith that of theWT strain atD6
(p 0.012) and D13 (p 0.012) post-challenge (Fig. 2B). Sur-
prisingly, at D2 after challenge, the level of luminal WT C. dif-
ficile was significantly lower than that of the CD0873 mutant
KSA1 (p  0.0079) (Fig. 2B), whereas no such difference was
seen in the feces. Similar to the results reported from the dix-
enicmodel above, KSA1 appears to be cleared from the caecum
at later stages of infection in this conventional model.
Gut colonization by the CD0873 mutant (KSA1) and WT
strains was further investigated by measuring the numbers of
bacteria associated with the caecal mucosa. Similar to the lumi-
nal analysis, at D2 after challenge a higher level of C. difficile
KSA1 was associated with the caecum than the WT strain
630erm (p 0.032). However, this level decreased andatD6 the
CD0873 mutant was significantly less associated to the mucosa
than theWTstrain (p 0.0079) (Fig. 2C). Finally, atD13, the level
of mucosa-associated bacteria was under the limit of detection in
both groups. These results demonstrate that the CD0873 mutant
exhibits a reduction in gut colonization in amousemodel of infec-
tion supporting the hypothesis that the lipoprotein CD0873 is a
new colonization factor ofC. difficile.
Figure 1. Evaluation of intestinal colonization by C. difficile in the com-
petitive dixenic mice infected by both 630erm and KSA1 C. difficile
strains, with equivalent inoculum. A, mean of C. difficile vegetative cells in
mouse feces at D1, D2, D3, D6, D7, D10, and D15 630erm (dark gray) and
KSA1 (light gray). B, mean of C. difficile vegetative cells in caecal contents of
mice sacrificed on D2, D7, and D15 for the 630erm group (circle) and KSA1
(triangle). C,mean of adherent C. difficile vegetative cells on caecal mucosa of
mice sacrificed on D2, D7, and D15. Data and error bars are the mean S.E.
calculatedon counts obtained frommiceper group (n 5). Thenonparamet-
ric Mann-Whitney U test was used to compare data between groups; *, p
0.05; **, p 0.01.
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Immunizationwith recombinant CD0873 protects mice from
colonization by C. difficile and elicits a strong secretory IgA
response
Given the importance of the lipoprotein CD0873 in C. diffi-
cile gut colonization, we assessed CD0873 as a vaccine candi-
date. Mice were intraperitoneally (IP) immunized with re-
combinant CD0873 formulated with Freund’s complete and
incomplete adjuvant, followed by oral challenge with WT
C. difficile 630erm. Gut colonization was compared with that
in nonimmunized mice infected with the sameWT strain. Sur-
prisingly, vaccinated mice did not develop diarrhea after chal-
lenge contrary to the control. This was associated with a lower
clinical score, meaning a lower weight loss and a better overall
activity than nonvaccinated mice (Fig. 3A). This apparent pro-
tection was associated with a late decrease, significant at D13
after challenge, of C. difficile gut colonization in vaccinated
mice compared with nonvaccinated mice, as shown in fecal
shedding (p 0.0075) (Fig. 3B) and luminal bacteria in caecum
(p 0.015) (Fig. 3C). At D13, the level of C. difficile associated
with the caecum was under the limit of detection for both
groups (Fig. 3D). As expected, the reduction in late stage colo-
nization in CD0873-vaccinated mice was correlated with a sig-
nificant production, after immunization, of anti-CD0873 IgG
(p 0.0019) in the serum and IgA in the intestine (p 0.0042).
These specific antibody levels were over 10-fold higher than in
the nonimmunized group (Fig. 3E). Conjoined, these results
further validate the lipoproteinCD0873 as a colonization factor
ofC. difficile. The data demonstrate that elicitation of a specific
systemic and mucosal immune response after vaccination with
recombinant CD0873 can protect against C. difficilemorbidity
in mice.
Themolecular structure of CD0873
Considering the role of CD0873 in in vitro C. difficile adher-
ence (13) and in in vivo colonization, it was of interest to deter-
mine the structure of this protein to provide further molecular
insight into its biological function. The structure of CD0873
was determined in three conditions, providing different infor-
mation on ligand-binding. The closed, ligand-bound structure
was determined to a resolution of 1.35Å; the semi-open, ligand-
bound structure was determined to 1.80 Å; and the open,
ligand-free structure was determined to 2.50 Å (Fig. 4, A–C).
Crystallographic and refinement statistics are given in Table 1.
The recombinant plasmid, pNIC_KSA1, coded for Ser-25 to
Glu-340 as the signal peptide of CD0873 is predicted to be
cleaved before Cys-24 in the native form (resulting in the
mature lipoprotein) (13), with Glu-43 to Gln-339 visible in the
structures. CD0873 assumes a typical Class I (17) or Cluster B
(18) SBP-fold. The protein possesses two domains, each con-
sisting of an -- sandwich joined by three loops that form a
hinge. The ligand-binding site is formed by the interface
between the two domains.
The closed structure has a tyrosine molecule (retained dur-
ing purification) bound (Fig. 4, A and D). The same pocket has
a polyethylene glycol (PEG)molecule bound (acquired from the
crystallizationmedium, Fig. 4, B and E) in the semi-open struc-
ture. The open structure does not have any ligand bound
(Fig. 4C). These high resolution structures provide a first
“glimpse” of the physiological ligand-binding pocket of
CD0873. The DALI server (19) identified two proteins with
similar structures: VC_1101 from Vibrio cholerae (Z  42.0,
id  38%, PDB code 3LKV) and SP1069 from Streptococcus
pneumoniae (Z  41.3, id  36%, PDB code 3LFT). CD0873
superposes on VC_1101 and SP1069 with RMSDs of 0.85 and
1.18 Å, respectively. Notably, all three structures have an aro-
matic amino acid bound. CD0873 has a tyrosine molecule
bound,whereasVC_1101 has phenylalanine bound and SP1069
has tryptophan bound. Comparison of the structures shows
that the proteins share a commonmechanism of binding to the
amino and acid groups, but show sequence differences that
account for their side chain preferences (Fig. 5).
Figure 2. Evaluation of intestinal colonization by C. difficile in conven-
tional mice infected by 630erm or KSA1 C. difficile strains. A, mean of
C. difficile vegetative cells in mouse feces at D1, D2, D3, D6, D7, D10, and D15
for the 2 groups 630erm (dark gray) and KSA1 (light gray). B, mean of C. dif-
ficile vegetative cells in caecal contents of mice sacrificed on D2, D7, and D15
for the 630erm group (circle) and KSA1 (triangle). C,mean of adherent C. dif-
ficile vegetative cells on caecal mucosa ofmice sacrificed on D2, D7, and D15.
Data and error bars are the mean S.E. calculated on counts obtained from
mice per group (n 5). The nonparametricMann-WhitneyU test was used to
compare data between groups; *, p 0.05; **, p 0.01; ***, p 0,001.
Molecular features of lipoprotein CD0873 fromC. difficile
15852 J. Biol. Chem. (2019) 294(43) 15850–15861
 at U
N
IV
 O
F EX
ETER on N
ovem
ber 1, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Differential scanning fluorimetry
The interaction of CD0873 with tyrosine was confirmed bio-
physically. The stability of the CD0873 protein was assessed in
the presence of 20 natural amino acids using differential scan-
ning fluorimetry (DSF) (20, 21). Refolded protein was used to
ensure no amino acids remained bound from expression. Cor-
rect refolding of the protein was confirmed using CD (data not
shown). DSF analysis strongly suggested, in agreement with the
crystallization studies, that CD0873 specifically binds tyrosine
(Fig. 6A; p  0.0001). To further characterize the interaction,
we determined the dose dependence of protein-ligand binding.
These data (Fig. 6B) suggested a dissociation constant KD (the
concentration where the protein is half-bound with ligand) of
94 7 M. These experiments have confirmed that the C. dif-
ficile adhesin CD0873 is a tyrosine substrate-binding protein of
an ABC transporter system.
Discussion
Here we show that CD0873 is an interesting vaccine candi-
date due to its key role in disease. The detailed structure of this
antigen serves as a basis for a specific subunit vaccine forC. dif-
ficile and also deciphers why the antigen is required biologically
by this pathogen. For the first timewe have demonstrated the in
vivo role of CD0873 inC. difficile intestinal colonization. In our
Figure 3. Effects of CD0873 immunization on C. difficile intestinal colonization in mice. A, survey of mouse weight expressed as mean of percentage of
initialmouseweight for nonimmunizedmouse group (630erm) and immunizedmouse group (immunized 630erm). B,mean of C. difficile vegetative cells
inmouse feces at D1, D2, D3, D6, D8, and D13 for the immunized group (immunized 630erm) (light gray) and the nonimmunized control group (630erm)
(dark gray). C,mean of C. difficile vegetative cells in caecal contents ofmice sacrificed onD6 andD13 for the immunized group (immunized 630erm) (circle)
and the nonimmunized control group (630erm) (squares).D,mean of adherent C. difficile vegetative cells on caecal mucosa ofmice sacrificed onD6 andD13
for the immunized group (immunized 630erm) (circle) and the nonimmunized control group (630erm) (squares). Data for the unimmunizedmice in B–D
is for comparison and represented from the data in Fig. 2. E, levels of specific Igs directed to CD0873 inmouse sera (IgG) ormouse feces (IgA) before (black) and
after immunization (gray). A–D, the nonparametric Mann-Whitney U test was used to compare data between groups. E, data were analyzed by a paired t test.
Normalitywas verifiedby the Shapiro-Wilk test andKolmogorov-Smirnov test. Data and error bars are themean S.E. calculatedoncounts obtained frommice
per group (n 5). *, p 0.05; **, p 0.01.
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dixenic mouse model, competition between the parental strain
and the CD0873 mutant strain led to lower numbers of the
mutant in the feces, caeca, and mucosa, relative to the parental
WT strain. This persistence in the intestinal tract by the paren-
tal strain can thus be attributed to the expression of CD0873.
This observation further supports previous findings of the up-
regulation of CD0873 upon binding to Caco2 cells as well the
direct adherence of CD0873 to enterocytes (13, 22). To rein-
force these data, we used a conventionalmurinemodel inwhich
we also observed a defect in long-term colonization for the
CD0873-deficient C. difficile strain. This observation aligns
with the previous reports that an isogenic CD0873 mutant of
C. difficile shows dramatically reduced adherence to Caco-2
enterocytes in vitro (13). In ourmurinemodels, dysbiosis allows
theWTC. difficile to proliferate and establish infection. Recent
studies have shown that the specific ability ofC. difficile to gen-
erate p-cresol, as the main fermentation product of tyrosine, is
key to this pathogen’s ability to cause disease. This is supported
by the observation that aC. difficilemutant defective in metab-
olizing tyrosine to p-cresol shows a fitness disadvantage in a
murinemodel of infection, a similar phenotype to that reported
here for our CD0873 mutant (14, 15, 23). The bacteriostatic
properties of p-cresol, which C. difficile itself can tolerate,
provides these bacteria with a competitive advantage over
other gut microflora, enabling them to proliferate and cause
CDI (14, 15).
It is interesting to note that many clinical strains have a
reduced ability to produce p-cresol and this has been correlated
with a convergent loss of two genes from a neighboring ABC
transporter, CD0876 andCD0877 (24). The solute binding pro-
tein CD0876 has 70% identity to CD0873 and due to minimal
differences in residues in the present structures demonstrated
to be involved in formation of the ligand-binding site, we pro-
pose CD0876 to also be a tyrosine transporter. However,
CD0877, theATP-binding protein of theCD0875-7ABC trans-
port system, has 88% identity to CD0874, and the former is also
missing in these clinical isolates that exhibit reduced p-cresol
production (24). It is therefore possible that CD0876 is also a
tyrosine-binding protein and that the reduction in p-cresol
observed in these clinical strains is due to deletion of the ATP-
binding protein, CD0877. This possibility arises from the obser-
vation that the solute binding component of ABC- transport
systems provide specificity and are subsequently able to form
functional transport systems with reciprocal permeases and
ATP-binding proteins (25). Therefore, inactivation of CD0873,
resulting in a lack of tyrosine uptake, may lead to less p-cresol
being produced by C. difficile and thus a faster restoration of
normal intestinal microbiota of mice. In agreement with this
Figure 4. Themolecular structure of CD0873 and ligand electron density. A, closed, ligand-bound conformation. B, open, ligand-bound conformation. C,
open, ligand-free conformation. Domain 1 is shown in blue, the hinge region in gray, and domain 2 in green. Each domain has an -- sandwich-fold. The
closed conformation binds a tyrosine molecule at the interface between the two domains, which is likely to be the physiological ligand, whereas the open,
ligand-bound conformation binds a PEG molecule, which will be a crystallographic artifact. D, tyrosine density for the closed, ligand-bound structure. The
density is from the round of refinement immediately after molecular replacement. E, polder map of PGE density for the open, ligand-bound structure. Both
images show 2Fo Fc in blue at 1.5 and Fo Fc in green at 3.
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hypothesis, our KSA1 strain was cleared more rapidly than a
WT strain of C. difficile expressing CD0873 in our models of
infection. This hypothesis also is supported by the recent obser-
vation that a C. difficilemutant defective in metabolizing tyro-
sine to p-cresol also shows a fitness disadvantage in a murine
model of infection (15). The convergent loss of CD0876 and
CD0877 from clinical isolates may arise from the high numbers
of C. difficile present during infection, with an associated ele-
vated level of p-cresol generating a selection pressure to lose
one of the two tyrosine transport systems to stabilize the pro-
duction of this bacteriostatic compound. CD0873 is retained
over CD0876 potentially due to its presence providing an
advantageous adherent phenotype although this role in patho-
genesis is yet to be fully elucidated.
The structural and biophysical data presented here unequiv-
ocally demonstrate that tyrosine is the preferred ligand for
CD0873. The binding sites of CD0873, VC_1101 (V. cholerae),
and SP1069 (S. pneumoniae) are largely similar with important
variations in two residues that are likely to affect the specificity
of the three proteins (Fig. 5). The exquisite specificity of
CD0873 for tyrosine is likely achieved through the tyrosine OH
group. This is hydrogen bonded to the side chain of Glu-263,
and to the main chain carbonyls of Val-235 and Pro-236
through a water molecule. In VC_1101 and SP1069, Glu-263 is
replaced by an alanine: the lack of an appropriate hydrogen
bond donor in these proteins explains their preference formore
hydrophobic amino acids. Gln-284 in SP1069 aids binding of
tryptophan through a hydrogen bond to the indole nitrogen;
this glutamine is replaced by a tyrosine in CD0873 and
VC_1101, which prevents binding of the larger tryptophan side
chain through steric hindrance.When the proposed alternative
tyrosine transporter, CD0876, is modeled against CD0873, an
alanine at position 262 in CD0873 is replaced with a serine in
CD0876. The hydroxyl group on this serine may affect the
hydrogen bonding to the hydroxyl group of tyrosine although a
structure of CD0876would be required to confirm any effect on
binding. As expected, the 18 residues at the N terminus of
CD0873 were not ordered in the crystal structures. The fact
that 18 N-terminal amino acids are not visible in any of the
structures also aligns with previous conclusions that bacterial
lipoproteins, and specifically SBPs, are connected to their
membrane anchor via a disordered N-terminal linker (26, 27).
These natively disordered juxtamembrane sequences encode
information for the sorting of lipoproteins, and provide confor-
mational flexibility to allow for correct positioning in themem-
brane. This is consistent with the role of CD0873 as an adhesin,
allowing it to be presented outside the S-layer, thus facilitating
its accessibility to antibodies, correlating with our previous
observations that antibodies against CD0873 can inhibit
binding of the bacteria to enterocytes (13). There are several
proteins that have been determined to possess dual roles as a
substrate-binding protein and an adhesin. PEB1a fromCampy-
lobacter jejuni, which binds glutamate and aspartate, possesses
a protruding strand-turn-strand motif that was speculated to
potentially be responsible for the adhesive role of the protein
(28, 29). Lam29 from Lactobacillus mucosae appears to be
responsible for the import of cysteine and is also capable of
binding to human blood group antigens A and B (30). It may,
Table 1
Crystallographic and refinement statistics
Crystallographic statistics Closed, ligand-bound Open, ligand-bound Open, ligand-free
Space group C2 P212121 P212121
Unit cell dimensions (Å, °) 131.1, 42.4, 56.2 38.0, 57.5, 148.5 40.4, 62.5, 146.1
90, 94.8, 90 90, 90, 90 90, 90, 90
Resolution 55.98–7.27	a 74.26–9.00	 146.10–8.67	
(1.37–1.35) (1.84–1.80) (2.61–2.50)
Rmerge 0.133	 0.297 (6.455) 0.085	 0.237 (1.483) 0.055	 0.158 (0.673)
Rmeas 0.138	 0.309 (6.880) 0.089	 0.250 (1.561) 0.061	 0.177 (0.796)
Rpim 0.037	 0.086 (2.319) 0.028	 0.077 (0.483) 0.026	 0.079 (0.344)
CC1/2 0.997	 0.997 (0.327) 0.993	 0.993 (0.721) 1.000	 0.998 (0.782)

I/I 30.2	 9.7 (1.7) 16.4	 7.0 (1.8) 17.7	 6.2 (1.9)
Total number of reflections 11,357	 1,693,479 (58,056) 4,916	 615,303 (35,222) 2,640	 101,849 (9,836)
Number of unique reflections 481	 67,816 (3,424) 322	 31,122 (1,758) 370	 12,793 (1,285)
Multiplicity 23.6	 25.0 (17.0) 15.3	 19.8 (20.0) 7.1	 8.0 (7.7)
Completeness (%) 99.8	 99.9 (98.8) 99.9	 99.9 (98.3) 96.1	 95.9 (80.2)
Refinement statistics
Rwork/Rfree 0.149/0.186 0.204/0.239 0.251/0.310
RMSDs
Bond lengths (Å) 0.016 0.012 0.009
Bond angles (°) 1.802 1.557 1.280
Ramachandran statistics (%)
Favored 97.4 97.6 93.2
Allowed 2.3 2.0 6.2
Outliers 0.3 0.4 0.7
Average B-factors (Å2)
Protein 18.6 30.5 68.2
Active site ligand 11.1 60.1 NAb
Other ligands 38.5 55.5 NA
Water 32.7 36.6 42.7
Number of atoms
Protein 2269 2234 2200
Active site ligand 13 10 NA
Other ligands 23 31 NA
Water 307 143 12
PDB code 6HNI 6HNJ 6HNK
a Inner shell statistics are given in square brackets, outer shell statistics are given in round brackets.
b NA, not applicable.
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therefore, be possible that adhesin-SBPs interact with glycans
found on the surface of host cells, however, more work is
required to identify a host receptor for CD0873.
Targeting colonization factors in a vaccine strategy against
C. difficile aims to neutralize bacterial propagation in the gut,
limiting the infection process and bacterial dissemination to
the environment. To this end, several vaccine candidates have
been tested in different models and via different routes of
immunization (7). Here we evaluated the efficacy of an intra-
peritoneal immunization strategy using purified CD0873 pro-
tein, observing a significant decrease of intestinal colonization
in the immunized mice compared with the nonimmunized
Figure 5. Ligand binding of CD0873, VC_1101, and SP1069. Themethod of ligand binding is largely conserved between the three proteins with variations
in two residues that appear to control substrate selectivity. VC_1101, which binds phenylalanine, can be considered the “default.” Ala-246 in VC_1101 and
Ala-268 in SP1069 are replaced by Glu-263 in CD0873, which forms a hydrogen bond to the hydroxyl of tyrosine, which is also stabilized by a hydrogen bond
to a water, which is, in turn, stabilized by Val-235 and Pro-236. Tyr-279 in CD0873 and Tyr-262 in VC_1101 are replaced by Gln-284 in SP1069. The smaller side
chain reduces steric hindrance, allowing tryptophan to bind, which is stabilized by a hydrogen bond to the side chain carbonyl of the glutamine. Residues
shown as a ball and stickmodels interact with the ligand through hydrogen bonds, shown in green. Residues shown as red lines interact through van derWaals
forces.
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mice. This was correlated with the production of specific sIgA
and IgG to CD0873 in the immunized mice. Moreover, com-
pared with the nonimmunized mice, the immunized mice pre-
sented a decrease in the severity of the infection characterized
by a lack of weight loss and diarrhea. There is a precedent for
using bacterial adhesins as vaccine candidates, with numerous
bacterial adhesins also characterized as lipoproteins, similar to
CD0873, including the adhesin PsaA, a solute-binding lipopro-
tein of the Mn2 ABC transporter of S. pneumoniae (31–33).
However, how many of these molecules function in a broader
context of disease is often unclear. This study, through struc-
tural analysis, reveals a biochemical rationale for why CD0873
is required for colonization. The rate of progress into the design
of more specific vaccines against bacterial pathogens is being
increased through detailed structural knowledge of promising
candidates (34–36). The work presented here not only demon-
strates that CD0873 is a potential vaccine candidate for the
prevention of colonization by C. difficile but also provides the
structural information to be able to further develop improved
subunit vaccines and aid in a deeper understanding of funda-
mental C. difficile biology.
Experimental procedures
Bacterial strains and growth conditions
C. difficile strains were grown at 37 °C in an anaerobic work
station (Don Whitley, United Kingdom) in an atmosphere of
10% CO2, 10% H2, and 80% N2, using prereduced brain heart
Figure 6. Characterization of the CD0873 protein in the presence of amino acids determined by thermal shift assay. A, stability of CD0873 in the
presence of 20 amino acids. Increased melting temperature (Tm) of CD0873 (***, p 0.0001, ANOVA with Tukey’s post hoc test) in the presence of tyrosine
suggests interaction of CD0873 with tyrosine. Glutamic and aspartic acid both slightly destabilize the protein (p  0.01). B, binding kinetics of CD0873 for
tyrosine. CD0873 binds to tyrosine in a dose-dependentmanner, showing a dissociation constant KD of 94 7M. Experimentswere performed in 6 replicates
and the data are representative of two experiments.
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infusion broth or agar (Oxoid). The followingC. difficile strains
were used in this study: 630erm, WT (37), and a CD0873
mutant, KSA1 (C. difficile 630ermCD0873(::ermB::317 318;
Eryr)) ((13)). For molecular cloning Escherichia coli C43(DE3)
was routinely cultured in lysogeny broth (LB) with shaking at
200 rpm or on LB agar at 37 °C. For protein expression studies
E. coli cells were grown in 2 YT liquidmedium.When appro-
priate, antibiotics were added at the following concentrations:
kanamycin, 50 g/ml; thiamphenicol, 15 g/ml; and erythro-
mycin, 5 g/ml.
Competitive colonization assay, dixenicmousemodel
Twenty axenic C3H/HeJ female mice (6 weeks old) from
INRA, Orle´ans, France, were infected with vegetative cells of
WT C. difficile (630erm, 5.7 105 CFU/mouse) and a C. dif-
ficile CD0873 mutant strain, KSA1 (630ermCD0873, 4 
105 CFU/mouse). The gavage suspension was prepared from
two overnight cultures. Vegetative forms were counted by
microscopy with aMalassez unit. The fitness and development
capacity of KSA1 was compared with that of the WT strain by
monitoring each of the bacterial populations from the feces,
caecum luminal contents, and washed caecal tissues through-
out the trial. Feces were collected at D1, D2, D3, D6, D7, D10,
and D15. In addition, at D2, D7, and D15 after challenge, five
mice per group were sacrificed tomonitor luminal bacteria and
bacteria adhering to the cecum. Caeca were removed, caecal
contents collected, and caeca were washed three times and all
sampleswereweighed.Caecum-adherent bacterial countswere
determined after mixing washed caecum in a PBS/Tween 80
(10%) solution with Ultra-Turrax (IKA) for 1 min on ice. Bac-
terial shedding in feces, luminal, and adherent bacterial counts
were determined after successive dilutions of samples, in PBS,
were cultured on BHI-horse blood 4% agar plates for 48 h at
37 °C in an anaerobic chamber. The CD0873 mutant strain,
KSA1, numberswere detected after culture onBHI-horse blood
4% agar plates containing 4g/ml of erythromycin.Numbers of
the 630ermWT strain were determined after culture on BHI-
horse blood 4% agar plates and subtraction of KSA1 numbers.
Data are expressed in cfu/mg of feces and cfu/g of caecal sam-
ple. The limit of detection of C. difficile by this technique was 1
cfu/mg of feces or 10 cfu/g of caecal sample.
Conventional mousemodel of colonization
Two groups of 15 C57Bl/6 female mice (6 weeks old) from
Charles River Laboratories (France) received an antibiotic
treatment in drinking water for 7 days. The mixture of antibi-
otics was composed of kanamycin (0.4 mg/ml), gentamicin
(0.035 mg/ml), colistin (850 U/ml), metronidazole (0.215
mg/ml), and vancomycin (0.045 mg/ml) ((16)). The concentra-
tion of the antimicrobial mixture was calculated based on the
average weight of mice and their expected water consumption.
On the third day of treatment a dose of clindamycin (10mg/kg)
was administered intraperitoneally. One day after the end of
antibiotic treatment, both groups were orally challenged with
the same amount of vegetative C. difficile cells. One group of
mice was infected with the WT 630erm strain (WT) and the
second group with KSA1 (630ermCD0873 mutant strain).
At D1, D2, D3, D6, D8, and D13 post-challenge, feces were
collected and bacterial fecal shedding was monitored. At D2,
D6, andD13 post-challenge, fivemice per groupwere sacrificed
to monitor luminal bacteria and bacteria adhering to the cae-
cum. Samples were analyzed as described previously as for the
dixenic competition assay. C. difficile WT strain was detected
on BHI-horse blood 4% agar plates and KSA1 mutant strain on
BHI-horse blood 4%, erythromycin, 4 g/ml, agar plates.
Immunization assay
One group of 15 C57Bl/6 female mice (6 weeks old) received
three times, every 15 days, one dose of recombinant CD0873
(50 g/kg) in Freund’s adjuvant (complete for the first immu-
nization and incomplete for the second and third immuniza-
tions, Sigma) by intraperitoneal injection (purification of
recombinant CD0873 protein detailed below). Before the first
dose and 15 days after the last, blood and feces were sampled to
analyze anti-CD0873 systemic IgG and local IgA responses,
respectively. Blood was collected by submandibular bleeding
under anesthesia (ketamine 1000, 100mg/kg, Rompun 2%, 0.25
ml/kg). One fecal sample permouse was suspended in 500l of
PBS and protease inhibitor mixture (Roche Diagnostics). After
centrifugation at 12,000  g for 10 min at 4 °C, supernatants
were used for anti-CD0873 IgA detection by ELISA.
Seven days after the last immunization, mice received an
antibiotic treatment in drinking water for 7 days as described
previously (16). Mice were then orally challenged with WT
C. difficile (630erm, 2.3 105 cfu). At D1, D2, D3, D6, D8, and
D13 post-challenge, feces were collected and bacterial fecal
shedding was monitored. At D7 and D15 post-challenge, five
mice per group were sacrificed tomonitor luminal bacteria and
bacteria adhering to the caecum. After challenge, weight loss
was also monitored. Animals with a weight loss of more than
20% and/or a significant decrease of activity were euthanized to
limit animal suffering. Results were compared with the nonim-
munized group challenged with 630erm from the coloniza-
tion assay in the conventional mouse model. Data were repre-
sented to reduce the number of animals used in these studies.
Detection of anti-CD0873 antibodies
Anti-CD0873 IgG and IgAwere detected in serum and feces,
respectively, by indirect ELISA as described previously (38).
Briefly, 96-wellmicrotiter plates (MaxiSorp,Nunc)were coated
with 5 g of recombinant purified CD0873 protein. Fecal
supernatants were tested at a dilution of 1:2 andmouse sera at a
dilution of 1:20. After washing, anti-CD0873 antibodies were
detected by successive incubations for 30 min at 37 °C with a
goat anti-mouse IgG or IgA conjugated to biotin (1:20,000 and
1:10,000 dilution, respectively; Sigma) and for 30 min at 37 °C
with a streptavidin-horseradish peroxidase conjugate (1:5,000
dilution; Thermo Scientific). All samples were treated simulta-
neously and tested in duplicate to avoid inter-assay variation.
Assays with antigen in the absence of sera served as negative
controls.
Statistical analysis
For non-normally distributed data from the C. difficile gut
colonization analysis in dixenic and conventional mouse mod-
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els, the Mann-Whitney U test was used. For antibody produc-
tion evaluation, data were analyzed by a paired t test. Normality
was verified by the Shapiro-Wilk test andKolmogorov Smirnov
test. A p value of less than 0.05 was considered to indicate sta-
tistical significance. Differential scanning fluorimetry results
were analyzed using an ANOVA test with Tukey post hoc test
using GraphPad version 8.2.0.
Protein expression and purification
E. coli C43(DE3) cells harboring the pNIC_KSA1 vector (13)
were grown in 2 YT media supplemented with 50 g/ml of
kanamycin. Cells were grown at 37 °C to anA590 of 0.5. Expres-
sion of the His-tagged recombinant protein was induced by
addition of isopropyl 1-thio--D-galactopyranoside (0.5 mM)
and the temperature reduced to 20 °C. Bacteria were harvested
after 20 h, and suspended in 20mMTris-HCl (pH 8.0), and 0.5 M
NaCl (Buffer A). The cells were lysed using a Soniprep 150
sonicator (MSE) with a medium probe. The lysate was clarified
by centrifuging at 20,000  g for 30 min at 4 °C. The superna-
tant was loaded on to a HisTrap Crude FF column (GE Health-
care). The column was washed with Buffer A supplemented
with 25 mM imidazole-HCl (pH 8.0), and the protein eluted
with buffer A supplemented with 250 mM imidazole-HCl (pH
8.0). His-taggedCD0873was then loaded onto aHiLoad 16/600
pg Superdex 200 column (GE Healthcare) and eluted isocrati-
cally into 10mMHEPES (pH 7.0) and 0.5 MNaCl (Buffer B). The
chromatography steps were performed on an A¨KTAxpress
chromatography system.
For preparation of tag-free CD0873,25mg of affinity puri-
fied protein was incubated at 4 °C for 43 h with 250 g of TEV
protease (His-tagged) (39). To remove residual undigested
CD0873 and the TEV enzyme the sample was then loaded over
a His GraviTrap column (GE Healthcare) and the flow through
was retained. His tag cleavage was confirmed by SDS-PAGE.
For DSF and CD the untagged CD0873 protein was unfolded
then refolded to remove any tyrosine bound during expression.
Unfolding was performed by dialyzing the protein against 8 M
urea. The denatured protein was refolded stepwise by dialysis
with 6, 4, 2, and 1 M urea and finally Buffer C (50 mM borate-
NaOH and 50 mM NaCl, pH 9.0). The refolded protein was
loaded onto a HiLoad 16/600 pg Superdex 200 column (GE
Healthcare) and eluted isocratically with Buffer C. The cor-
rectly refolded protein was concentrated to 1 mg/ml using a
Vivaspin 6 centrifugal concentrator (MWCO 10,000 Da). For
DSF experiments, the solvent Buffer Cwas replacedwith Buffer
B using a PD-10 desalting column (GE Healthcare).
X-ray crystallographic studies
CD0873 was concentrated in a spin concentrator to a range
of concentrations and screened against a wide range of molec-
ular dimension crystallization conditions by sitting drop vapor
diffusion. Crystals were observed from protein concentrated to
7.6 mg ml1 mixed 1:1 (protein:condition) with Structure
Screen 1&2 (SS1&2) condition G4 (0.1 M sodium HEPES, pH
7.5, 20% (w/v) PEG 10,000), 2.8 mg ml1 mixed 2:1 with the
BCS Screen condition A12 (0.1 MMES, pH 6.5, with 2% each of
PEG 400, 500 MME, 600, 1000, 2000, 3350, 4000, 5000 MME,
6000, 8000 and 10,000), and 2.8 mg ml1 mixed 1:1 with the
BCS Screen condition C6 (0.2 M potassium chloride, 7.5% PEG
6000, 7.5% PEG 8,000, 7.5% PEG 10,000). The crystals were
cryoprotected by addition of 1 l of reservoir solution and data
were collected from two crystals grown in SS1&2 G4 on beam-
line I04, a single crystal grown in BCS A12 on beamline I03 and
a single crystal grown in BCSC6 on beamline I04-1 at Diamond
Light Source, UK. The data were integrated with Dials (40) and
scaled with Aimless (41).
The closed, ligand-bound structure (from SS1&2 G4 crys-
tals) was solved by molecular replacement in Phaser (42) using
VC_1101 (PDB 3LKV) as a model. The structure was refined
and completed with Coot (43) and Refmac5 (44). Poor density
was observed for Ser-328 to Asn-331 so this region was mod-
eledwith Rosetta (45). Themodeled residues fit the density well
both before and after final rounds of refinement. The two
domains from the closed, ligand-bound structure were used
separately in molecular replacement to solve the open, ligand-
bound structure (BCS A12) and the open, ligand-free structure
(BCS C6), which were refined and completed with Coot and
Refmac5. All structures were validated with MolProbity (46).
Differential scanning fluorometry
DSF assays were set up in a 384-well white quantitative PCR
plates and sealed with optical tape (Applied Biosystems). Sam-
ples contained 0.1 mg/ml (2.95 M) of CD0873, 10 mM HEPES
(pH 7.0), 150 mM NaCl, and 5 SYPRO Orange dye in a final
reaction volume of 10l. Amino acids (10 concentrated stock
solutions inwater, except tyrosine, whichwas less concentrated
due to poor solubility in water) were added to a final concen-
tration of 1mM for the initial screen, and between 1 nM and 1.93
mM for the dilution series of tyrosine. All samples were pre-
pared in six replicates. The DSF reactions were performed
using a QuantStudio 6 Flex Real-Time PCR System (Applied
Biosystems). To generate the melting curves, samples were
heated in a gradient from 25 to 99.9 °C (0.017 °C rise/s) and
the fluorescence was measured at every 0.2 °C rise. The
Boltzmann-derived melting temperature (Tm) was deter-
mined using Protein Thermal ShiftTM Software version 1.3
(Applied Biosystems), and plots were produced using
GraphPad Prism 8.2.0. The dissociation constant KD was
determined using the equation,
Tm  TL   TH 	 TL

 1 	 P 	 KD 	 Y	  P  Y	  KD2 	 4 
 P 
 Y	2 
 P  (Eq. 1)
where KD is the dissociation constant, and P the protein con-
centration (in the same units that were used for the ligand con-
centrations); and TH and TL are the melting temperatures at
infinite ligand concentration and no ligand concentration,
respectively (21). Protein concentration was treated as a con-
stant, and KD, TH, and TL fitted to the data using Equation 1.
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